The strategy toward personalized medicine in radiation oncology, nuclear medicine, and diagnostic and interventional radiology demands a specific set of assays for individualized estimation of radiation load for safety concerns and prognosis of normal tissue reactions caused by ionizing radiation. Apparently, it seems reasonable to use validated radiation dosimetric biomarkers for these purposes. However, a number of gaps in knowledge and methodological limitations still have to be resolved until dosimetric biomarkers will start to play a valuable role in clinical practice beyond radiation protection and radiation medicine. An extensive international multicenter research is necessary to improve the methodology of clinical applications of biodosimetry. That became a rationale for launching the IAEA Coordinated Research Project E35010 MEDBIODOSE: "Applications of Biological Dosimetry Methods in Radiation Oncology, Nuclear Medicine, and Diagnostic and Interventional Radiology." At the 2 Coordination Meeting on MEDBIODOSE (18-22 February 2019, Recife, Brazil), participants reported progress in the usage of biological dosimetry for genotoxicity assessment and/or individualization of radiotherapy treatment plans. Another avenue of research was the prognosis of normal tissue toxicity and cancer risk prediction using biomarkers' yield measured in vivo or after ex vivo irradiation of patients' cells. Other important areas are mechanisms of cytogenetic radiation response, validation of new radiation biomarkers, development of innovative techniques, automated and high-throughput assays for biodosimetry, and the overall improvement of biodosimetry service. An important aspect of clinical application of biodosimetry is standardization of techniques and unification of approaches to data interpretation. The new IAEA Biodosimetry/Radiobiology Laboratory, which is being established, will provide support for this activity. The declared lab's mission includes, among other tasks, a harmonization of the biodosimetry applications with relevant international standards, guidelines on good laboratory practice, and the IAEA EPR-Biodosimetry manual.

中文翻译：

---

医学放射学实践中的辐射暴露生物标志物：合作研究和国际原子能机构（IAEA）生物剂量法/放射生物学实验室的作用。

放射肿瘤学，核医学以及诊断和介入放射学中个性化医学的策略需要一套特定的化验方法，以针对安全性问题和由电离辐射引起的正常组织反应的预后，对辐射负荷进行个性化估计。显然，出于这些目的使用经过验证的辐射剂量生物标记似乎是合理的。但是，在剂量学生物标记物将开始在放射防护和放射医学之外的临床实践中发挥重要作用之前，仍然需要解决知识和方法学限制方面的许多空白。有必要进行广泛的国际多中心研究，以改进生物剂量测定的临床应用方法。这成为启动国际原子能机构协调研究项目E35010 MEDBIODOSE的理由：“生物剂量学方法在放射肿瘤学，核医学以及诊断和介入放射学中的应用。” 在第2届MEDBIODOSE协调会议（2019年2月18日至22日，巴西累西腓）上，与会人员报告了使用生物剂量学进行遗传毒性评估和/或放射治疗方案个体化的进展。另一研究途径是使用体内或体外照射患者细胞后测得的生物标志物的产量预测正常组织毒性和预测癌症风险。其他重要领域包括细胞遗传辐射反应的机制，新的辐射生物标记物的验证，创新技术的开发，生物剂量学的自动化和高通量分析以及生物剂量学服务的整体改善。生物剂量学临床应用的一个重要方面是技术的标准化和数据解释方法的统一。正在建立的新的原子能机构生物剂量/放射生物学实验室将为这项活动提供支持。宣布的实验室的任务除其他任务外，还包括使生物剂量学应用程序与相关国际标准，良好实验室规范指南和IAEA EPR生物剂量学手册相协调。